Thomas Jonassen
Fortune : 5 M $ au 31/05/2026
Fortune : 5 M $ au 31/05/2026
Thomas Jonassen is the founder.
Dr. Jonassen was the founder of Action Pharma A, founded in 2000, holding the title of Chief Scientific Officer.
Dr. Jonassen is also the founder of TXP Pharma GmbH,ResoTher Pharma AS.
Dr. Jonassen is currently an Associate Professor at the University of Copenhagen and the Chief Scientific Officer at SynAct Pharma AB starting in 2024.
Dr. Jonassen holds a doctorate from the University of Copenhagen.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SYNACT PHARMA AB 4,77 % | 19/12/2025 | 2 545 320 ( 4,77 % ) | 5 M $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| SYNACT PHARMA AB | Directeur Technique/Scientifique/R&D | - |
University of Copenhagen
University of Copenhagen Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
ResoTher Pharma AS
ResoTher Pharma AS Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops peptide-based drugs | Fondateur | - |
| Sociétés | Poste | Fin |
|---|---|---|
TXP Pharma GmbH | Fondateur | - |
Action Pharma A/S
Action Pharma A/S BiotechnologyHealth Technology Manufactures biopharmaceutical products | Fondateur | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 5 |
|---|---|
University of Copenhagen
University of Copenhagen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Action Pharma A/S
Action Pharma A/S BiotechnologyHealth Technology Manufactures biopharmaceutical products | Health Technology |
SynAct Pharma AB
SynAct Pharma AB Pharmaceuticals: MajorHealth Technology Provides pharmaceutical drugs for treatment inflammatory diseases | Health Technology |
TXP Pharma GmbH | |
ResoTher Pharma AS
ResoTher Pharma AS Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops peptide-based drugs | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national